- Home
- AG vs HRMY Comparison
AG vs HRMY Comparison
Compare AG & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- HRMY
- Stock Information
- Founded
- AG 1979
- HRMY 2017
- Country
- AG Canada
- HRMY United States
- Employees
- AG N/A
- HRMY N/A
- Industry
- AG Precious Metals
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- AG Basic Materials
- HRMY Health Care
- Exchange
- AG Nasdaq
- HRMY Nasdaq
- Market Cap
- AG 4.1B
- HRMY 2.0B
- IPO Year
- AG N/A
- HRMY 2020
- Fundamental
- Price
- AG $8.46
- HRMY $32.16
- Analyst Decision
- AG Buy
- HRMY Strong Buy
- Analyst Count
- AG 2
- HRMY 9
- Target Price
- AG $8.75
- HRMY $54.22
- AVG Volume (30 Days)
- AG 27.3M
- HRMY 620.8K
- Earning Date
- AG 07-31-2025
- HRMY 08-05-2025
- Dividend Yield
- AG 0.23%
- HRMY N/A
- EPS Growth
- AG N/A
- HRMY 13.13
- EPS
- AG N/A
- HRMY 2.62
- Revenue
- AG $698,532,000.00
- HRMY $744,852,000.00
- Revenue This Year
- AG $68.65
- HRMY $20.10
- Revenue Next Year
- AG $9.36
- HRMY $18.01
- P/E Ratio
- AG N/A
- HRMY $12.27
- Revenue Growth
- AG 33.60
- HRMY 20.62
- 52 Week Low
- AG $4.43
- HRMY $26.47
- 52 Week High
- AG $8.74
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- AG 64.22
- HRMY 43.25
- Support Level
- AG $8.22
- HRMY $31.70
- Resistance Level
- AG $8.57
- HRMY $33.69
- Average True Range (ATR)
- AG 0.32
- HRMY 0.89
- MACD
- AG -0.05
- HRMY -0.10
- Stochastic Oscillator
- AG 69.23
- HRMY 37.30
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.